The Bay Area-based pharma company Verseon began designing small-molecule drugs on a computational platform in 2002. That is well before most of the companies like Recursion and Exscientia now called AI drug discovery firms existed, and two decades before the launch of ChatGPT. Today, Verseon’s website states that its programs feature novel candidates that cannot…
Why AI alone won’t resolve drug discovery challenges
Big Pharma and researchers are sharpening their focus on AI to speed drug discovery. But the path to fully AI-driven drug discovery faces substantial hurdles, according to Adityo Prakash, CEO of Verseon. “When it comes to drug discovery, AI has a data problem with which the pharmaceutical industry has not yet come to terms,” he…
Generative AI could boost biopharma R&D productivity by billions, according to McKinsey
Generative AI stands to add trillions of dollars of value to the world economy, according to a recent McKinsey report. The consultancy noted that about three-quarters of the value of generative AI spans four areas — customer operations, marketing and sales, software engineering and R&D. The latter could see a 12% annual lift in global…
Verseon’s hybrid AI platform aims to unlock a universe of drug candidates
The clinical-stage company Verseon (Fremont, California) is unique among companies exploring the use of AI in drug discovery given its focus on what it calls the “uncharted” chemical space. While Big Pharma companies typically test compounds from their collections for specific diseases, these collections often have constraints and overlapping compounds. Adityo Prakash, CEO of Verseon,…



